In a groundbreaking collaboration,Parse Biosciences’ GigaLab and Vevo Therapeutics have unveiled what they claim is the largest single-cell dataset ever assembled.Dubbed Tahoe-100M, this massive dataset encompasses a staggering 100 million cells, spanning 60,000 conditions, 1,200 drug treatments, and 50 tumor models. Vevo plans to leverage this unprecedented resource to accelerate its artificial intelligence (AI)-driven drug finding efforts.
The partnership harnessed the single-cell RNA sequencing prowess of Parse, combined with the high-throughput sequencing capabilities of Ultima Genomics. Remarkably,this aspiring project was completed in just one month.
“The dataset is an important step forward for the Vevo team and the Mosaic platform,” said Johnny yu, PhD, Vevo’s CSO and co-founder. Mosaic is designed to generate high-resolution in vivo data at scale. The company asserts that its platform can measure how drugs impact cells from hundreds of patients, generating millions of data points on changes in gene expression.
The Tahoe-100 dataset consists entirely of data derived from perturbing diseased cells and “is 50x larger than all the public drug-perturbed single-cell data,” according to Vevo CEO and co-founder Nima Alidoust. Like many companies in the field,vevo is betting that AI-based tools can analyze this wealth of information and uncover intriguing connections between drugs and disease pathways,perhaps leading to novel therapeutic opportunities. A major challenge for drug developers is obtaining sufficient data to train models capable of handling such complex tasks.
“The tahoe-100M atlas entirely changes the game, allowing us to train much larger AI models that can better learn the language of the cell,” noted Hani Goodarzi, PhD, Vevo co-founder, associate professor at the University of California, San Francisco, and a core investigator at Arc Institute.
Vevo intends to combine data from its single-cell atlas with AI models to identify novel targets and pathways for major cancer subtypes, as well as drug compounds that target these pathways. “Over the past two years, we’ve refined our platform and with access to the Parse GigaLab, we can now generate the data needed to power AI-based drug discovery at massive speed and scale,” Yu said.
Vevo plans to announce additional collaborations centered around the dataset in the first quarter of next year.
This partnership also highlights the advantages of Parse’s Evercode technology, which powers GigaLab. Specifically, its ability to “deliver speed, quality, and immense scalability,” said Alex Rosenberg, Parse’s CEO and co-founder. GigaLab, an initiative launched by Parse earlier this year, targets researchers working on projects involving 10 million single cells or more for a range of applications. At the time of its launch, the company claimed a capacity of profiling 2.5 billion cells per year, with plans to expand further.
Beyond the Vevo partnership, parse is exploring other large-scale projects that could leverage GigaLab’s single-cell sequencing capabilities, including collaborations with biopharma companies and large research consortia.
A groundbreaking discovery in the realm of ancient Egyptian history has sent ripples of excitement through the archaeological community. Researchers have unearthed a remarkably well-preserved tomb dating back to the 18th Dynasty, a period renowned for its powerful pharaohs and intricate burial practices.
The tomb, located in the Valley of the Kings, was discovered by a team of archaeologists from the egyptian Ministry of Tourism and Antiquities.”This is a truly exceptional find,” said Dr. Ahmed Abbas, the lead archaeologist on the project.”The tomb is in an astounding state of preservation, offering us a rare glimpse into the funerary customs and beliefs of this fascinating era.”
“The walls are adorned with vibrant paintings depicting scenes from the afterlife, and the sarcophagus itself is intricately carved with hieroglyphs,” Dr. Abbas added. “We believe the tomb belonged to a high-ranking official, possibly a vizier or a priest, given the opulence of the burial goods found inside.”
Among the artifacts discovered were gold jewelry, alabaster vases, and a collection of papyrus scrolls. Experts are currently working to decipher the scrolls, which are expected to shed further light on the tomb’s occupant and the social and religious context of the time.
the discovery is considered a major breakthrough in Egyptology, providing invaluable insights into the lives and beliefs of ancient Egyptians. The Egyptian goverment plans to open the tomb to the public in the near future, allowing visitors from around the world to witness this remarkable piece of history firsthand.
The Valley of the Kings, located on the west bank of the Nile River opposite Luxor, has been a treasure trove of archaeological discoveries for centuries. It is the final resting place of many pharaohs, including Tutankhamun, whose tomb was famously discovered in 1922.
This latest find promises to add another chapter to the rich and fascinating history of ancient Egypt, captivating the imaginations of historians and the public alike.
## Vevo’s Tahoe-100M: A One-Month Sprint too the Largest Single-Cell Dataset Yet
**World Today News:** Today, we speak with Dr. Hani Goodarzi, Co-founder of Vevo Therapeutics adn Associate Professor at the University of California, San Francisco, about the groundbreaking partnership with parse Biosciences that resulted in tahoe-100M, the largest single-cell dataset to date. Dr. Goodarzi, thank you for joining us.
**Dr. Goodarzi:** It’s a pleasure to be here.
**World Today News:** Let’s talk about Tahoe-100M. What makes this dataset so unique, and what are the potential implications for drug revelation?
**Dr.Goodarzi:** Tahoe-100M is a game-changer for a few reasons. First, its sheer size is unprecedented: 100 million cells covering 60,000 conditions, 1,200 drug treatments, and 50 tumor models. This level of detail allows us to see the intricate workings of cells under various conditions, which is crucial for understanding how diseases develop and how drugs interact within complex biological systems.
Second, we were able to generate this immense dataset in just one month, thanks to the innovative single-cell RNA sequencing technology from Parse Biosciences and the high-throughput capabilities of Ultima Genomics. This unprecedented speed demonstrates the power of these new technologies to accelerate research substantially.
**World Today News:** You mentioned the use of AI in your drug discovery process. How will Tahoe-100M be leveraged for AI-driven research?
**Dr.Goodarzi:** The abundance of data in Tahoe-100M is precisely what AI algorithms need to truly flourish. Traditionally, training AI models for drug discovery has been hindered by limited data. Tahoe-100M allows us to build much larger AI models capable of learning complex patterns and relationships within cellular data. Essentially, it teaches the AI the “language” of the cell, allowing it to identify novel drug targets, predict drug responses, and uncover new pathways involved in disease.
**world Today News:** What are some specific therapeutic areas that Vevo is focusing on with this new dataset?
**Dr. goodarzi:** We are currently focusing on major cancer subtypes. We believe Tahoe-100M will enable us to identify new drug targets and pathways specific to these challenging diseases. We’re also looking for compounds that can effectively target these pathways, perhaps leading to novel and more effective cancer treatments.
**World Today News:** What are your plans for making Tahoe-100M accessible to the broader research community?
**Dr. Goodarzi:** we believe in open science and collaboration. While details are still being finalized, we intend to make Tahoe-100M accessible to researchers through partnerships and collaborations, allowing the scientific community to fully leverage this unprecedented resource.
**World Today News:** This collaboration with Parse Biosciences highlights the importance of these new single-cell sequencing technologies. Can you elaborate on that?
**Dr.Goodarzi:** Absolutely. Trascend’s GigaLab, powered by Parse’s Evercode technology, has been instrumental in this breakthrough. It represents a notable leap forward in terms of speed, quality, and scalability. GigaLab’s ability to handle massive datasets opens up exciting possibilities for ambitious research projects that were previously unattainable.
**World Today News:** what are your expectations for the future of single-cell data in drug discovery?
**Dr. Goodarzi:** With collaborative efforts like Tahoe-100M, we’re entering a new era in drug discovery where single-cell data holds immense potential. More comprehensive understanding of cellular behavior will undoubtedly lead to breakthroughs in treating challenging diseases. I believe this is just the beginning,and the future of personalized medicine relies heavily on harnessing the power of single-cell data.
**World Today News:** Dr. Goodarzi, thank you for sharing your insights on this groundbreaking development.
**Dr. goodarzi:** Thank you for having me.
